Nelarabine

Active ingredient: Nelarabine

In short: Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regime

Forms & strengthsNelarbine injection 250 mg/50 mL (5 mg/mL) is supplied as a clear, colorless, sterile solution in Type I, clear glass single-dose vials with a gray bromobutyl rubber stopper (not made with natural rubber latex) and an aluminum seal with a snap-off cap.
LabelXGen Pharmaceuticals DJB, Inc.
Label updatedSep 29, 2026

What is Nelarabine used for?

Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens.

âš  Boxed warning (FDA's strongest warning)

Severe neurologic adverse reactions have been reported with the use of nelarabine injection. These adverse reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of adverse reactions associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré syndrome

.

Full recovery from these adverse reactions has not always occurred with cessation of therapy with nelarabine injection. Monitor frequently for signs and symptoms of neurologic toxicity during treatment with nelarabine injection. Discontinue nelarabine injection for neurologic adverse reactions of NCI Common Toxicity Criteria for Adverse Events (CTCAE) Grade 2 or greater

.

Nelarabine dosage

This product is for intravenous use only.

Adult Dosage: The recommended adult dose of nelarabine injection is 1500 mg/m

2 administered by intravenous infusion over 2 hours on Days 1, 3, and 5 repeated every 21 days. Administer nelarabine injection undiluted.

Pediatric Dosage: The recommended pediatric dose of nelarabine injection is 650 mg/m

2 administered by intravenous infusion over 1 hour daily for 5 consecutive days repeated every 21 days. Administer nelarabine injection undiluted.

The recommended duration of treatment for adult and pediatric patients has not been clearly established. In clinical trials, treatment was generally continued until there was evidence of disease progression, the patient experienced unacceptable toxicity, the patient became a candidate for hematopoietic stem cell transplantation (HSCT), or the patient no longer continued to benefit from treatment.

Discontinue nelarabine injection if the patient develops a neurologic adverse reaction of NCI CTCAE Grade 2 or greater. Dosage may be delayed for other toxicity, including hematologic toxicity

.

Nelarabine injection has not been studied in patients with renal or hepatic dysfunction

. No dose adjustment is recommended for patients with a creatinine clearance (CLCr) greater than or equal to 50 mL/min

.

There are insufficient data to support a dose recommendation for patients with a CLCr less than 50 mL/min.

Take precautions against hyperuricemia (e.g., hydration, urine alkalinization, and prophylaxis with allopurinol)

.

Handling: Nelarabine injection is a hazardous drug. Caution should be used during handling and preparation. Use of gloves and other protective clothing to prevent skin contact is recommended. Proper aseptic technique should be used. Guidelines for proper handling and disposal of anticancer drugs have been published.

1

Preparation and Administration: Administer nelarabine injection undiluted. Transfer the appropriate dose of nelarabine injection into polyvinylchloride (PVC) infusion bags or glass containers and administer as a 2-hour infusion in adult patients and as a 1-hour infusion in pediatric patients.

Prior to administration, inspect the drug product visually for particulate matter and discoloration.

Discard unused portion.

Stability: Nelarabine injection is stable in PVC infusion bags and glass containers for up to 8 hours at up to 30°C.

How to take Nelarabine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hematologic Adverse Reactions

Advise patients that leukopenia, thrombocytopenia, anemia, and neutropenia, including febrile neutropenia, have been associated with nelarabine injection.

Advise patients that complete blood counts, including platelets, will be monitored regularly during treatment

.

​

Embryo-Fetal Toxicity

Advise pregnant females of reproductive potential and males with female partners of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with nelarabine injection. Instruct females to inform their physician of a known or suspected pregnancy.

Advise male patients with partners of reproductive potential to use condoms during treatment with nelarabine injection and for 3 months after the last dose

.

Tumor Lysis Syndrome

Advise patients of the risk of tumor lysis syndrome

.

Vaccinations

Instruct patients not to receive live vaccines during treatment with nelarabine injection

. …

Warnings & precautions

Do not take this medicine if: None.

Nervous system adverse reactions of any grade were reported for 223 (76%) adult patients across the Phase I and Phase II trials, and Grade 3 or higher (severe, life-threatening, or fatal) adverse reactions were reported for 55 (19%) patients following initiation of nelarabine injection therapy

. Based on patients with complete data, the median time to onset of first event is 5 days from start of first infusion (range: 1-166), and the median duration is 6 days (range: 1-393 days).

Nervous system adverse reactions of any grade were reported for 69 (42%) pediatric patients across the Phase I and Phase II trials, and Grade 3 or higher (severe, life-threatening, or fatal) adverse reactions were reported for 25 (15%) patients following initiation of nelarabine injection therapy

. Based on patients with complete data, the median time to onset of first event is 8 days from start of first infusion (range: 1-269), and the median duration is 2 days (range: 1-82 days).

Common signs and symptoms of nelarabine injection-related neurotoxicity include somnolence, headache, paresthesia and dysesthesia, dizziness, neuropathy (sensory and motor), cerebellar disturbances and tremor. Severe neurologic toxicity can manifest as coma, status epilepticus, craniospinal demyelination, or ascending neuropathy similar in presentation to Guillain-Barré syndrome.

Full recovery from these adverse reactions has not always occurred with cessation of therapy with nelarabine injection. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events.

Monitor patients frequently for signs and symptoms of neurologic toxicity during and for at least 24 hours after completion of treatment with nelarabine injection. …

Nelarabine side effects

The following clinically-significant adverse reactions are discussed in greater detail in other sections of the label:

Neurologic

Hematologic

Tumor Lysis Syndrome

Effects on Ability to Drive and Use Machines

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Relapsed or Refractory T-ALL and T-LBL

Nelarabine injection was studied in 459 patients in Phase I and Phase II clinical trials.

Adult Patient:

The safety profile of nelarabine injection is based on data from 103 adult patients treated with the recommended dose and schedule in 2 studies: an adult T- ALL/T-cell T-LBL trial and an adult chronic lymphocytic leukemia trial.

The most common adverse reactions in adults were fatigue; gastrointestinal disorders (nausea, diarrhea, vomiting, and constipation); hematologic disorders (anemia, neutropenia, and thrombocytopenia); respiratory disorders (cough and dyspnea); nervous system disorders (somnolence and dizziness); and pyrexia.

The most common adverse reactions in adults by Body System, including severe or life-threatening adverse reactions (NCI CTCAE Grade 3 or Grade 4) and fatal adverse reactions (Grade 5) are shown in Table 1.

Table 1. …

Drug interactions

Administration of nelarabine injection in combination with adenosine deaminase (ADA) inhibitors, such as pentostatin, is not recommended

.

About this medicine

Nelarabine is a prodrug of the cytotoxic deoxyguanosine analogue, 9-β-

D-arabinofuranosylguanine (ara-G).

The chemical name for nelarabine is 2-amino-9-β-

D-arabinofuranosyl-6-methoxy-9

H-purine. It has the molecular formula C

11H

15N

5O

5 and a molecular weight of 297.27. Nelarabine has the following structural formula:

Nelarabine is slightly soluble to soluble in water and melts with decomposition between 209°C and 217°C.

Nelarabine injection is supplied as a clear, colorless, sterile solution in glass single-dose vials. Each vial contains 250 mg of nelarabine (5 mg nelarabine per mL) and the inactive ingredient sodium chloride (4.5 mg per mL) in Water for Injection, USP. Nelarabine injection is intended for intravenous infusion.

Hydrochloric acid and sodium hydroxide may have been used to adjust the pH. The solution pH ranges from 5.0 to 7.0.

How it works: Nelarabine is a prodrug of the deoxyguanosine analogue 9-β- D-arabinofuranosylguanine (ara-G), a nucleoside metabolic inhibitor. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a1cc1580-50d9-4b9b-a002-1fc6686a9515. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate